Common painkiller may boost lung cancer Drug's power

NCT ID NCT04184921

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding aspirin to the targeted drug osimertinib helps control advanced EGFR-positive non-small cell lung cancer. 216 participants received the combination as their first treatment. The goal was to see if it delays cancer progression and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

osimertinib and aspirin

What this could lead to

If it works, this combination could help control advanced EGFR-positive lung cancer longer than osimertinib alone.

What could go wrong

This is a small, early-phase trial without a comparison group, so results may not confirm benefit. Aspirin also carries bleeding risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER NON-SMALL CELL STAGE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Daping Hospital

    Chongqing, Chongqing Municipality, 400000, China